SV2017005380A - Tratamientos conjuntos con anticuerpos anti cd40 - Google Patents

Tratamientos conjuntos con anticuerpos anti cd40

Info

Publication number
SV2017005380A
SV2017005380A SV2017005380A SV2017005380A SV2017005380A SV 2017005380 A SV2017005380 A SV 2017005380A SV 2017005380 A SV2017005380 A SV 2017005380A SV 2017005380 A SV2017005380 A SV 2017005380A SV 2017005380 A SV2017005380 A SV 2017005380A
Authority
SV
El Salvador
Prior art keywords
treatments
antibodies
joint
joint treatments
antigen
Prior art date
Application number
SV2017005380A
Other languages
English (en)
Inventor
Peter Ellmark
Per Norlen
Niina Veitonmäki
Original Assignee
Alligator Bioscience Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53836090&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SV2017005380(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB1414270.7A external-priority patent/GB201414270D0/en
Priority claimed from GBGB1507541.9A external-priority patent/GB201507541D0/en
Application filed by Alligator Bioscience Ab filed Critical Alligator Bioscience Ab
Publication of SV2017005380A publication Critical patent/SV2017005380A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A TRATAMIENTOS CONJUNTOS PARA TRATAR UN TUMOR SÓLIDO EN UN SUJETO. LOS TRATAMIENTOS CONJUNTOS COMPRENDEN (A) UN ANTICUERPO, O LA PORCIÓN DE FIJACIÓN AL ANTÍGENO DE ESTE, QUE SE FIJA ESPECÍFICAMENTE A CD40, Y (B) UN AGENTE INMUNOTERAPÉUTICO ADICIONAL CON EFICACIA EN EL TRATAMIENTO DEL CÁNCER, EN DONDE EL AGENTE NO ES UN ANTICUERPO ANTI-CD4O NI EL FRAGMENTO DE FIJACIÓN AL ANTÍGENO DE ESTE. LA INVENCIÓN TAMBIÉN SE REFIERE A KITS Y MÉTODOS PARA USAR TALES TRATAMIENTOS
SV2017005380A 2014-08-12 2017-02-07 Tratamientos conjuntos con anticuerpos anti cd40 SV2017005380A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1414270.7A GB201414270D0 (en) 2014-08-12 2014-08-12 Antibodies
GB201422614 2014-12-18
GBGB1507541.9A GB201507541D0 (en) 2015-05-01 2015-05-01 Antibodies

Publications (1)

Publication Number Publication Date
SV2017005380A true SV2017005380A (es) 2018-09-14

Family

ID=53836090

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2017005380A SV2017005380A (es) 2014-08-12 2017-02-07 Tratamientos conjuntos con anticuerpos anti cd40

Country Status (25)

Country Link
US (3) US11149090B2 (es)
EP (2) EP3552665A3 (es)
JP (1) JP6654187B2 (es)
KR (1) KR102443258B1 (es)
CN (2) CN114099671A (es)
AU (1) AU2015303164B2 (es)
CA (1) CA2957146A1 (es)
CL (1) CL2017000335A1 (es)
CO (1) CO2017001317A2 (es)
CR (1) CR20170096A (es)
DK (1) DK3180087T3 (es)
EA (1) EA201790339A1 (es)
EC (1) ECSP17008984A (es)
ES (1) ES2725463T3 (es)
IL (1) IL250512B (es)
MA (1) MA47472A (es)
MX (1) MX2017001864A (es)
NI (1) NI201700015A (es)
NZ (1) NZ729270A (es)
PE (1) PE20170680A1 (es)
PH (1) PH12017500229A1 (es)
SG (1) SG11201701070WA (es)
SV (1) SV2017005380A (es)
UA (1) UA119783C2 (es)
WO (1) WO2016023960A1 (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190122889A (ko) 2011-04-29 2019-10-30 아펙시젠, 인코포레이티드 항-cd40 항체 및 사용 방법
JP6367836B2 (ja) 2013-02-07 2018-08-01 ザ ジェネラル ホスピタル コーポレイション Ｔ制御性細胞の増殖または枯渇方法
AR097584A1 (es) 2013-09-12 2016-03-23 Hoffmann La Roche Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano
JP6502959B2 (ja) 2013-12-12 2019-04-17 上海恒瑞医薬有限公司 Ｐｄ−１抗体、その抗原結合性断片及びそれらの医学的使用
TWI754621B (zh) 2015-11-18 2022-02-11 美商默沙東藥廠 Pd1及／或 lag3結合劑
MX2018007089A (es) 2015-12-14 2019-01-30 Macrogenics Inc Moleculas biespecificas que tienen inmunorreactividad con pd-1 y ctla-4, y metodos de uso de las mismas.
CN109476745B (zh) * 2016-05-13 2023-11-24 综合医院公司 拮抗性抗肿瘤坏死因子受体超家族抗体
BR112018076281A2 (pt) 2016-06-20 2019-03-26 Kymab Limited imunocitocina, uso de uma imunocitocina, método, composição farmacêutica, método para tratar uma doença proliferativa em um animal, ácido nucleico, vetor, hospedeiro e anticorpo ou fragmento do mesmo
CN117247458A (zh) 2016-07-14 2023-12-19 健玛保 针对cd40和cd137的多特异性抗体
EP3504239B1 (en) 2016-08-25 2024-05-29 F. Hoffmann-La Roche AG Intermittent dosing of an anti-csf-1r antibody in combination with macrophage activating agent
WO2018078620A1 (en) 2016-10-25 2018-05-03 Urogen Pharma Ltd. Immunomodulating treatments of body cavities
JP2019534292A (ja) * 2016-11-02 2019-11-28 アペクシジェン， インコーポレイテッド 組み合わせた抗ｃｄ４０抗体および使用方法
EP3558360A1 (en) 2016-12-22 2019-10-30 F. Hoffmann-La Roche AG Treatment of tumors with an anti-csf-1r antibody in combination with an anti-pd-l1 antibody after failure of anti-pd-l1/pd1 treatment
JP7181878B2 (ja) * 2017-01-13 2022-12-01 タイチョウ ハンチョン バイオファーマシューティクス インコーポレイテッド Ｐｄ－１に対するモノクローナル抗体及びその適用
EP3589324A1 (en) * 2017-03-03 2020-01-08 Janssen Biotech, Inc. Co-therapy comprising a small molecule csf-1r inhibitor and an agonistic antibody that specifically binds cd40 for the treatment of cancer
EP3675877A1 (en) 2017-08-31 2020-07-08 Multimmune GmbH Hsp70 based combination therapy
KR20210038839A (ko) * 2018-03-13 2021-04-08 히버셀, 인크. 베타 글루칸 및 cd40 효능제 조합 면역요법
EP3807320A4 (en) * 2018-06-12 2022-03-23 BioNTech US Inc. POLYTHERAPY INCLUDING A VACCINE BASED ON NEO ANTIGENS
JP2021528393A (ja) 2018-06-15 2021-10-21 フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド 後細胞シグナル伝達因子の調節による免疫活性の上昇
KR20210095891A (ko) 2018-11-23 2021-08-03 스트라이크 파마 아베 이중 특이적 접합체
TW202039558A (zh) * 2018-11-30 2020-11-01 大陸商江蘇恆瑞醫藥股份有限公司 抗ｃｄ４０抗體、其抗原結合片段及其醫藥用途
EP3962493A2 (en) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V, Inc. Methods of modulating immune activity/level of irf or sting or of treating cancer, comprising the administration of a sting modulator and/or purinergic receptor modulator or postcellular signaling factor
MA56027A (fr) * 2019-05-28 2022-04-06 Janssen Biotech Inc Procédé de fourniture d'une administration sûre d'un anticorps anti-cd40
WO2021048135A1 (en) 2019-09-09 2021-03-18 Basilea Pharmaceutica International AG Pharmaceutical combinations comprising a furazanobenzimidazoles and a cd40 agonist for use in the treatment of neoplastic diseases
US20230114107A1 (en) 2019-12-17 2023-04-13 Flagship Pioneering Innovations V, Inc. Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
CN114981435A (zh) * 2019-12-27 2022-08-30 因特欧力多公司 用于治疗癌症的抗癌免疫治疗组合物
GB202008003D0 (en) 2020-05-28 2020-07-15 Quine Medical Ab Anti-CD40 antibody
CA3184366A1 (en) 2020-06-29 2022-01-06 Darby Rye Schmidt Viruses engineered to promote thanotransmission and their use in treating cancer
WO2022036495A1 (en) 2020-08-17 2022-02-24 Utc Therapeutics Inc. Lymphocytes-antigen presenting cells co-stimulators and uses thereof
KR20230165276A (ko) 2021-03-31 2023-12-05 플래그쉽 파이어니어링 이노베이션스 브이, 인크. 타노트랜스미션 폴리펩티드 및 암의 치료에서의 이의 용도
EP4363059A1 (en) 2021-06-29 2024-05-08 Flagship Pioneering Innovations V, Inc. Immune cells engineered to promote thanotransmission and uses thereof
EP4415757A1 (en) * 2021-10-15 2024-08-21 The Rockefeller University Combination of anti-cd40 antibody and il-15 for treating cancer
WO2023247050A1 (en) 2022-06-23 2023-12-28 Alligator Bioscience Ab Combination therapies
US20240174732A1 (en) 2022-10-05 2024-05-30 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additional polypeptides and their use in treating cancer
US20240269251A1 (en) 2023-01-09 2024-08-15 Flagship Pioneering Innovations V, Inc. Genetic switches and their use in treating cancer

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6051228A (en) 1998-02-19 2000-04-18 Bristol-Myers Squibb Co. Antibodies against human CD40
WO2001083755A2 (en) 2000-04-28 2001-11-08 La Jolla Institute For Allergy And Immunology Human anti-cd40 antibodies and methods of making and using same
AU2002234572B2 (en) 2000-12-12 2006-07-06 Alligator Bioscience Ab A method for in vitro molecular evolution of protein function
CA2658221C (en) 2001-04-27 2012-11-27 Kyowa Hakko Kirin Co., Ltd. Anti-cd40 monoclonal antibody
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
US7432063B2 (en) 2002-02-14 2008-10-07 Kalobios Pharmaceuticals, Inc. Methods for affinity maturation
US20040110226A1 (en) 2002-03-01 2004-06-10 Xencor Antibody optimization
DE60312507T3 (de) 2002-05-17 2011-08-18 Alligator Bioscience Ab Eine methode zur in vitro molekularen evolution der proteinfunktion
CN101001872A (zh) * 2004-04-16 2007-07-18 宏观基因有限公司 FcγRIIB－特异性抗体及其使用方法
AU2005323515A1 (en) 2004-04-27 2006-07-13 Novartis Vaccines And Diagnostics, Inc. Antagonist anti-CD40 monoclonal antibodies and methods for their use
BRPI0610235B8 (pt) 2005-05-09 2021-05-25 Squibb & Sons Llc anticorpos monoclonais geneticamente modificados e diferentes daqueles encontrados na natureza, ou porção de ligação ao antígeno dos mesmos, usos terapêuticos dos mesmos, composições, imunoconjugado, molécula biespecífica compreendendo os mesmos, molécula de ácido nucléico e vetor de expressão
DE602006017690D1 (de) 2005-05-26 2010-12-02 Genentech Inc Humanisierte antikörper gegen cd40 und verfahren zu ihrer anwendung
GB0620894D0 (en) * 2006-10-20 2006-11-29 Univ Southampton Human immune therapies using a CD27 agonist alone or in combination with other immune modulators
AU2009206506B2 (en) 2008-01-23 2013-01-10 Xencor, Inc. Optimized CD40 antibodies and methods of using the same
CA2735421A1 (en) 2008-08-29 2010-03-04 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Delivery of a cd40 agonist to a tumor draining lymph node of a subject
TW201840336A (zh) 2011-08-01 2018-11-16 美商建南德克公司 利用pd-1軸結合拮抗劑及mek抑制劑治療癌症之方法
GB201115280D0 (en) 2011-09-05 2011-10-19 Alligator Bioscience Ab Antibodies, uses and methods
AR090263A1 (es) 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
US10533054B2 (en) * 2013-01-31 2020-01-14 Thomas Jefferson University Agonist fusion protein for CD40 and OX40 and methods of stimulating the immune system
EA201600474A1 (ru) 2013-12-20 2016-11-30 Ф. Хоффманн-Ля Рош Аг Комбинированная терапия с использованием антитела к ang2 и агониста cd40
TWI693232B (zh) 2014-06-26 2020-05-11 美商宏觀基因股份有限公司 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
EA201792273A1 (ru) 2015-04-17 2018-04-30 Бристол-Маерс Сквибб Компани Композиции, содержащие комбинацию анти-pd-1 антитела и другого антитела
PL3303395T3 (pl) 2015-05-29 2020-05-18 Abbvie Inc. Przeciwciała anty-cd40 i ich zastosowania
JP7350467B2 (ja) 2015-06-29 2023-09-26 ブリストル－マイヤーズ スクイブ カンパニー Ｃｄ４０に対する抗体
UY36757A (es) 2015-06-29 2016-12-30 Bristol Myers Squibb Company Una Corporación Del Estado De Delaware Anticuerpos monoclonales murinos contra cd40 con actividad agonista mejorada

Also Published As

Publication number Publication date
MA47472A (fr) 2019-12-18
NI201700015A (es) 2017-05-12
EP3180087B1 (en) 2019-03-13
EA201790339A1 (ru) 2017-06-30
ES2725463T3 (es) 2019-09-24
US11149090B2 (en) 2021-10-19
WO2016023960A1 (en) 2016-02-18
AU2015303164A1 (en) 2017-03-09
US20240228643A9 (en) 2024-07-11
ECSP17008984A (es) 2017-05-31
US20240132609A1 (en) 2024-04-25
AU2015303164B2 (en) 2020-10-29
EP3180087A1 (en) 2017-06-21
CL2017000335A1 (es) 2017-08-11
JP6654187B2 (ja) 2020-02-26
JP2017524715A (ja) 2017-08-31
DK3180087T3 (da) 2019-05-13
KR102443258B1 (ko) 2022-09-14
CN114099671A (zh) 2022-03-01
SG11201701070WA (en) 2017-03-30
US20210403589A1 (en) 2021-12-30
CA2957146A1 (en) 2016-02-18
EP3552665A3 (en) 2019-12-18
PE20170680A1 (es) 2017-06-14
CN106573981A (zh) 2017-04-19
PH12017500229A1 (en) 2017-07-10
CO2017001317A2 (es) 2017-08-10
BR112017002729A2 (pt) 2018-02-27
US20170226217A1 (en) 2017-08-10
NZ729270A (en) 2024-03-22
EP3552665A2 (en) 2019-10-16
MX2017001864A (es) 2017-08-02
IL250512A0 (en) 2017-03-30
CR20170096A (es) 2017-06-15
KR20170041790A (ko) 2017-04-17
UA119783C2 (uk) 2019-08-12
IL250512B (en) 2021-08-31

Similar Documents

Publication Publication Date Title
SV2017005380A (es) Tratamientos conjuntos con anticuerpos anti cd40
CO2018000809A2 (es) Anticuerpos para cd40
CL2017000285A1 (es) Terapia combinada para el tratamiento de un paramixovirus
EA201990296A1 (ru) Антитела против siglec-7 для лечения рака
ECSP17005649A (es) Anticuerpos anti-tau humanizados
BR112018013731A2 (pt) combinações anti-egfr para o tratamento de tumores
BR112018013733A2 (pt) combinações anti-cd20 para o tratamento de tumores a
BR112016005816A2 (pt) Combinação de anticorpos anti-lag-3 e anticorpos anti-pd-1 para tratar tumores
BR112016005303A2 (pt) anticorpos anti-b7-h1 para tratamento de tumores
BR112018014016A2 (pt) combinação de um agonista de ox40 e um agonista de anticorpo monoclonal 4-1bb para tratamento de câncer
MX2018008346A (es) Terapia de combinación de virus oncológico e inhibidor de punto de control.
EA201790192A1 (ru) СПОСОБ СНИЖЕНИЯ Fc-РЕЦЕПТОРНОГО СВЯЗЫВАНИЯ МОЛЕКУЛ СЫВОРОТОЧНОГО IgG У СУБЪЕКТА
EA201992251A1 (ru) Противораковые вакцины и способы лечения с их применением
MX2022008868A (es) Tratamiento del cancer con tg02.
BR112015030356A2 (pt) métodos de tratamento de uma taupatia
MX2016014306A (es) Marcadores para terapia con lipoproteinas de alta densidad (hdl).
CL2017002983A1 (es) Terapia combinada de un anticuerpo anti-cd-20 con un inhibidor de bcl-2 y un inhibidor de mdm2
EA201791736A1 (ru) Комбинированная терапия для лечения рака
AR101740A1 (es) Terapia de combinación y composiciones
BR112019001398A2 (pt) métodos para tratamento de câncer de próstata
BR112017025533A2 (pt) método para tratar câncer em um paciente humano
BR112017005235A2 (pt) vetores virais adeno-associados para o tratamento de glaucoma de miocilina (myoc)
CO2022009696A2 (es) Anticuerpo anti-lilrb1 y usos del mismo
BR112019008241A2 (pt) tratamento do prurigo nodular
EA201791819A1 (ru) Комбинированная терапия с применением конъюгата антитела против cd19 с лекарственным средством и винкристина